COR

Cencora Inc

Add to Watchlist

Advanced Chart

291.240

+0.550(+0.190%)

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

295.250

Open

290.870

VWAP

291.40

Vol

3.89M

Mkt Cap

56.45B

Low

290.030

Amount

1.13B

EV/EBITDA(TTM)

14.53

Total Shares

196.93M

62.39B

EV/OCF(TTM)

15.18

P/S(TTM)

0.18

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company is focused on improving the lives of people and animals around the world. It is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

86.67B

+6.36%

4.098

+9.87%

84.61B

+7.03%

3.832

+14.72%

80.29B

+8.14%

3.778

+13.12%

Estimates Revision

The market is revising Downward the revenue expectations for Cencora, Inc. (COR) for FY2025, with the revenue forecasts being adjusted by -0.43% over the past three months. During the same period, the stock price has changed by 14.04%.

Revenue Estimates for FY2025

Revise Downward

-0.43%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.66%

In Past 3 Month

Stock Price

Go Up

+14.04%

In Past 3 Month

11 Analyst Rating

11.28% Upside

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 324.10 USD with a low forecast of 274.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

3 Hold

0 Sell

Moderate Buy

11.28% Upside

Current: 291.240

Low

274.00

Averages

324.10

High

355.00

11.28% Upside

Current: 291.240

Low

274.00

Averages

324.10

High

355.00

Baird

David Rodgers

Buy

Maintains

$314 → $350

2025-05-08

Reason

Baird

David Rodgers

Price Target

$314 → $350

2025-05-08

Maintains

Buy

Reason

Citigroup

Michael Rollins

Strong Buy

Maintains

$330 → $355

2025-05-08

Reason

Citigroup

Michael Rollins

Price Target

$330 → $355

2025-05-08

Maintains

Strong Buy

Reason

UBS

Kevin Caliendo

Strong Buy

Maintains

$298 → $335

2025-04-29

Reason

UBS

Kevin Caliendo

Price Target

$298 → $335

2025-04-29

Maintains

Strong Buy

Reason

UBS raised the firm's price target on Cencora to $335 from $298 and keeps a Buy rating on the shares.

B of A Securities

Michael Funk

Hold

Maintains

$270 → $285

2025-04-11

Reason

B of A Securities

Michael Funk

Price Target

$270 → $285

2025-04-11

Maintains

Hold

Reason

Wells Fargo

Stephen Baxter

Hold

Maintains

$251 → $274

2025-03-14

Reason

Wells Fargo

Stephen Baxter

Price Target

$251 → $274

2025-03-14

Maintains

Hold

Reason

Wells Fargo raised the firm's price target on Cencora to $274 from $251 and keeps an Equal Weight rating on the shares. The firm is updating its model following Cencora's results and more recent guidance raise. Estimates for all years move higher based on U.S. strength, partially offset by lower International vs. Wells' previous model.

Evercore ISI Group

John Belton

Buy

Maintains

$270 → $280

2025-02-06

Reason

Evercore ISI Group

John Belton

Price Target

$270 → $280

2025-02-06

Maintains

Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 17.56, compared to its 5-year average forward P/E of 13.80. For a more detailed relative valuation and DCF analysis to assess Cencora Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Overvalued

5Y Average PE

13.80

Current PE

17.56

Overvalued PE

15.78

Undervalued PE

11.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Overvalued

5Y Average EV/EBITDA

10.01

Current EV/EBITDA

12.96

Overvalued EV/EBITDA

11.59

Undervalued EV/EBITDA

8.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

0.13

Current PS

0.17

Overvalued PS

0.15

Undervalued PS

0.11